Eli Lilly reported positive Phase 3 results for retatrutide, with participants losing up to 22.6% of body weight across two obesity trials. The company plans to seek FDA approval in 2027.
Wattbike has integrated with the EGYM ecosystem, enabling VO2 Max estimates and performance data to sync with Cardio BioAge scores for more personalized member experiences.